4 assets in Amyotrophic Lateral Sclerosis Type 19

Therapeutic assets addressing Amyotrophic Lateral Sclerosis Type 19, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Everolimus Amyotrophic Lateral Sclerosis Type 19	M.D. Anderson Cancer Center	P1	CC (43)
Neratinib Amyotrophic Lateral Sclerosis Type 19	M.D. Anderson Cancer Center	P1	CC (43)
Palbociclib Amyotrophic Lateral Sclerosis Type 19	M.D. Anderson Cancer Center	P1	CC (43)
Trametinib Amyotrophic Lateral Sclerosis Type 19	M.D. Anderson Cancer Center	P1	CC (43)